Lipocine Inc. Files 8-K Report
Ticker: LPCN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Lipocine filed a routine 8-K, no major news.
AI Summary
Lipocine Inc. filed an 8-K on January 13, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Lipocine Inc. is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard SEC report and does not disclose any new material risks or events.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- January 13, 2025 (date) — Date of Earliest Event Reported
- 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
- Salt Lake City, Utah 84108 (address) — Principal executive offices
- 001-36357 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Lipocine Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 13, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 13, 2025.
What is Lipocine Inc.'s principal executive office address?
Lipocine Inc.'s principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is Lipocine Inc.'s Commission File Number?
Lipocine Inc.'s Commission File Number is 001-36357.
Does this filing indicate any significant changes or material events for Lipocine Inc.?
Based on the provided text, this filing appears to be a routine report of 'Other Events' and 'Financial Statements and Exhibits' without specifying any significant new material events.
Filing Stats: 412 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-01-13 06:04:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 44KB
- form8-k_001.jpg (GRAPHIC) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 609KB
- ex99-1_002.jpg (GRAPHIC) — 1141KB
- ex99-1_003.jpg (GRAPHIC) — 939KB
- ex99-1_004.jpg (GRAPHIC) — 941KB
- ex99-1_005.jpg (GRAPHIC) — 540KB
- ex99-1_006.jpg (GRAPHIC) — 927KB
- ex99-1_007.jpg (GRAPHIC) — 834KB
- ex99-1_008.jpg (GRAPHIC) — 882KB
- ex99-1_009.jpg (GRAPHIC) — 911KB
- ex99-1_010.jpg (GRAPHIC) — 907KB
- ex99-1_011.jpg (GRAPHIC) — 669KB
- ex99-1_012.jpg (GRAPHIC) — 518KB
- ex99-1_013.jpg (GRAPHIC) — 1174KB
- ex99-1_014.jpg (GRAPHIC) — 1104KB
- ex99-1_015.jpg (GRAPHIC) — 1138KB
- ex99-1_016.jpg (GRAPHIC) — 1037KB
- ex99-1_017.jpg (GRAPHIC) — 620KB
- ex99-1_018.jpg (GRAPHIC) — 535KB
- ex99-1_019.jpg (GRAPHIC) — 716KB
- ex99-1_020.jpg (GRAPHIC) — 904KB
- ex99-1_021.jpg (GRAPHIC) — 814KB
- ex99-1_022.jpg (GRAPHIC) — 587KB
- ex99-1_023.jpg (GRAPHIC) — 1331KB
- ex99-1_024.jpg (GRAPHIC) — 750KB
- ex99-1_025.jpg (GRAPHIC) — 982KB
- ex99-1_026.jpg (GRAPHIC) — 849KB
- ex99-1_027.jpg (GRAPHIC) — 371KB
- ex99-1_028.jpg (GRAPHIC) — 655KB
- ex99-1_029.jpg (GRAPHIC) — 790KB
- ex99-1_030.jpg (GRAPHIC) — 1029KB
- ex99-1_031.jpg (GRAPHIC) — 324KB
- ex99-1_032.jpg (GRAPHIC) — 816KB
- ex99-1_033.jpg (GRAPHIC) — 1106KB
- ex99-1_034.jpg (GRAPHIC) — 654KB
- ex99-1_035.jpg (GRAPHIC) — 705KB
- ex99-1_036.jpg (GRAPHIC) — 953KB
- ex99-1_037.jpg (GRAPHIC) — 918KB
- ex99-1_038.jpg (GRAPHIC) — 732KB
- ex99-1_039.jpg (GRAPHIC) — 590KB
- ex99-1_040.jpg (GRAPHIC) — 915KB
- ex99-1_041.jpg (GRAPHIC) — 979KB
- ex99-1_042.jpg (GRAPHIC) — 539KB
- ex99-1_043.jpg (GRAPHIC) — 1096KB
- ex99-1_044.jpg (GRAPHIC) — 854KB
- ex99-1_045.jpg (GRAPHIC) — 687KB
- ex99-1_046.jpg (GRAPHIC) — 721KB
- 0001493152-25-001841.txt ( ) — 52226KB
- lpcn-20250113.xsd (EX-101.SCH) — 3KB
- lpcn-20250113_lab.xml (EX-101.LAB) — 33KB
- lpcn-20250113_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: January 13, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer